Palisade Bio (NASDAQ:PALI – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($2.32) earnings per share for the quarter, topping the consensus estimate of ($3.35) by $1.03, Zacks reports.
Palisade Bio Stock Performance
NASDAQ:PALI opened at $2.20 on Thursday. Palisade Bio has a fifty-two week low of $2.18 and a fifty-two week high of $22.35. The company has a 50 day simple moving average of $3.37 and a two-hundred day simple moving average of $4.21. The company has a market capitalization of $2.93 million, a PE ratio of -0.16 and a beta of 1.36.
Analysts Set New Price Targets
Separately, Maxim Group cut their target price on Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a report on Wednesday.
Palisade Bio Company Profile
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.
Featured Articles
- Five stocks we like better than Palisade Bio
- What is a Dividend King?
- Top 3 R&D-Driven Stocks Showing Strong Profit and Momentum
- Do ETFs Pay Dividends? What You Need to Know
- Shopify Stock Rally Continues: Why the Growth Story Isn’t Over
- What Are the U.K. Market Holidays? How to Invest and Trade
- Tariff Troubles: 3 Stocks Planning Higher Prices
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
